Search

  1. ProQR Update August 2022

    Community news

    … will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic … exclusively on accelerating the development of its Axiomer RNA-editing platform technology. Initial therapeutic areas …

    Axiomer RNA editing platform technology

  2. ProQR at TIDES to highlight our Axiomer technology

    Blog

    This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer RNA-editing platform technology.

    Two ProQRians standing outside TIDES EU 2022 Conference Entrance

  3. Exploring why companies partner their technology

    Blog

    … on developing potential medicines using our Axiomer™ RNA editing platform technology. Strategic collaborations … greater understanding, we can drive higher standards of RNA-editing, medicinal application, and effectiveness of our …

    Lenka

  6. Today marks an expansion of the ProQR and Lilly partnership

    News update

    … on developing potential medicines using our Axiomer RNA editing platform technology. Strategic collaborations … exclusively on furthering the development of our Axiomer RNA editing platform technology , which allows selective … in September 2021 , applied ProQR’s proprietary Axiomer™ RNA editing platform to target disorders of the liver and …

    Axiomer partnership

  7. “A new way of designing medicines”

    Story

    Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology makes it possible to use the cells own machinery to reverse mutations that cause a genetic disease. Read the interview.

    A photo of Bart Klein

  8. Project Lead, Investigator-Initiated Trials (Associate Director)

    Vacancy

    … of the communities we serve. Our proprietary Axiomer™ RNA editing technology platform enables the editing of … in RNA using the cells own editing machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase … currently untreatable diseases. By harnessing the power of RNA editing, we aim to create a world where genetics inform …

  9. Principal Scientist Liver

    Vacancy

    … of the communities we serve. Our proprietary Axiomer™ RNA editing technology platform enables the editing of … in RNA using the cells own editing machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase … currently untreatable diseases. By harnessing the power of RNA editing, we aim to create a world where genetics inform …